xbl novoskin preclinical study results

finally some good news from XBL. Well it sounds like good news anyway.

Anyone hold this stock and if so what you think of ann.

------------------------------------------------


NovoSkin successfully completes the first round of its pre-clinical study
Product efficacy shown in wound model
21 December 2007
Xceed Biotechnology Limited (ASX:XBL) (‘Xceed’) is pleased to advise that its subsidiary company, PolyNovo Biomaterials Ltd (‘PolyNovo’) has successfully concluded the first round of its pre-clinical study utilising its dermal matrix product (used to treat major skin loss) made from NovoSorb™.
Introduction
This study was commissioned by NovoSkin, PolyNovo’s joint venture with eminent burns surgeon Dr John Greenwood AM. The study and data analysis were performed by an independent accredited testing facility. The study has demonstrated the efficacy of the NovoSkin’s dermal matrix prototype in a wound model.
Summary and Key Findings
The study involved assessment of a dermal matrix prototype made from NovoSorb™ compared with natural healing and a global market leading dermal matrix product.
Natural healing resulted in severe contraction and scarring in all six wound sites.
The NovoSorb™ matrix and the current market leading product both resisted contraction with a reduction in the volume of scar tissue to similar degrees.
A normal epidermis (outer layer of skin) quickly formed over the NovoSorb™ matrix which led to complete healing of the wound site in all cases. This would create an option for the surgeon to apply skin grafts earlier and obtain better acceptance.
The current market leading product formed an ulcerated epidermis in all six wound sites.
No evidence of clinical infection was observed in the NovoSorb™ matrix filled wounds.
The current market leading product displayed infection in two of six wounds created for this study.
Dr Greenwood said “The dermal matrix in both sheep wound model and human cellular studies has demonstrated proof of design concept. The outstanding results from the prototype matrix gives us confidence that with continued optimisation our product will compete favourably with the existing dermal matrix products. The cellular studies also give us confidence that generational products can lead to replacement of the role of skin grafts. These products would reduce pain, scarring and enhance survival prospects of many patients”.
Dr Griffiths (CEO PolyNovo) said “We are very pleased with the data and generally with progress. Optimisation of the matrix and validation of the manufacturing are planned for early 2008. We will continue this study with statistically relevant numbers in mid 2008. We believe this will allow us to proceed with our application for human trials and commercialisation of the first generation products”.